by Todd Bishop on Aug 31, 2026 at 10:14 am August 31, 2026 at 10:14 am
A Kirkland, Wash.-based biotech company led by former Athira Pharma CEO Leen Kawas has raised $35 million in a Series A round led by Propel Bio Partners, the Los Angeles investment firm where Kawas is a co-founder and managing general partner.
EIT Pharma said Monday that the oversubscribed round also drew participation from Good Ventures, Arrowtown and others. The company said the money will support FDA review of lonafarnib, an oral treatment candidate for chronic hepatitis D, along with manufacturing and commercial preparations, subject to regulatory approval.
The Food and…
Read the full article at GEEKWIRE.COM


